332
Views
26
CrossRef citations to date
0
Altmetric
ENDOMETRIOSIS

PI3K/AKT pathway is altered in the endometriosis patient’s endometrium and presents differences according to severity stage

, , , , , & show all
Pages 436-440 | Received 25 Jun 2019, Accepted 11 Oct 2019, Published online: 22 Oct 2019

References

  • Child TJ, Tan SL. Endometriosis: aetiology, pathogenesis and treatment. Drugs. 2001;61(12):1735–1750.
  • Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010;362(25):2389–2398.
  • Fuldeore MJ, Soliman AM. Prevalence and symptomatic burden of diagnosed endometriosis in the United States: national estimates from a cross-sectional survey of 59,411 women. Gynecol Obstet Invest. 2017;82(5):453–461.
  • Meuleman C, Vandenabeele B, Fieuws S, et al. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil Steril. 2009;92(1):68–74.
  • Agarwal SK, Chapron C, Giudice LC, et al. Clinical diagnosis of endometriosis: a call to action. Am J Obstet Gynecol. 2019; 220:354–354.
  • Rawson JM. Prevalence of endometriosis in asymptomatic women. J Reprod Med. 1991;36(7):513–515.
  • Simoens S, Dunselman G, Dirksen C, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. 2012;27(5):1292–1299.
  • Nnoaham KE, Hummelshoj L, Webster P, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011;96(2):366–373.
  • Culley L, Law C, Hudson N, et al. The social and psychological impact of endometriosis on women's lives: a critical narrative review. Hum Reprod Update. 2013;19(6):625–639.
  • Grogan S, Turley E, Cole J. So many women suffer in silence': a thematic analysis of women's written accounts of coping with endometriosis. Psychol Health. 2018;33(11):1364–1378.
  • Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009;15(4):441–461.
  • Vercellini P, Vigano P, Somigliana E, et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261–275.
  • Che XH, Chen YC, Chen CL, et al. Non-hormonal targets underlying endometriosis: a focus on molecular mechanisms. Mol Reprod Dev. 2015;82(6):410–431.
  • Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13(22):2905–2927.
  • Hemmings BA, Restuccia DF. The PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 2015;7(4):a026609.
  • Lee II, Kim JJ. Influence of AKT on progesterone action in endometrial diseases. Biol Reprod. 2014;91(3):63.
  • Goswami A, Ranganathan P, Rangnekar VM. The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res. 2006;66(6):2889–2892.
  • De Santis MC, Sala V, Martini M, et al. PI3K signaling in tissue hyper-proliferation: from overgrowth syndromes to kidney cysts. Cancers (Basel). 2017;9(12):30.
  • Matson DR, Hardin H, Buehler D, et al. AKT activity is elevated in aggressive thyroid neoplasms where it promotes proliferation and invasion. Exp Mol Pathol. 2017;103(3):288–293.
  • Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60(24):7052–7056.
  • Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.
  • Varma R, Rollason T, Gupta JK, et al. Endometriosis and the neoplastic process. Reproduction. 2004;127(3):293–304.
  • Mafra FA, Christofolini DM, Cavalcanti V, et al. Aberrant telomerase expression in the endometrium of infertile women with deep endometriosis. Arch Med Res. 2014;45(1):31–35.
  • Gentilini D, Busacca M, Di FS, et al. PI3K/Akt and ERK1/2 signalling pathways are involved in endometrial cell migration induced by 17beta-estradiol and growth factors. Mol Hum Reprod. 2007;13(5):317–322.
  • Cinar O, Seval Y, Uz YH, et al. Differential regulation of Akt phosphorylation in endometriosis. Reprod Biomed Online. 2009;19(6):864–871.
  • Kim TH, Yu Y, Luo L, et al. Activated AKT pathway promotes establishment of endometriosis. Endocrinology. 2014;155(5):1921–1930.
  • Zhang H, Zhao X, Liu S, et al. 17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway. Mol Cell Endocrinol. 2010;317(1-2):31–43.
  • Leconte M, Nicco C, Ngo C, et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol. 2011;179(2):880–889.
  • Vercellini P, Fedele L, Aimi G, et al. Association between endometriosis stage, lesion type, patient characteristics and severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients. Hum Reprod. 2007;22(1):266–271.
  • Grummer R. Translational animal models to study endometriosis-associated infertility. Semin Reprod Med. 2013;31:125–132.
  • Meresman GF, Baranao RI, Tenenbaum A, et al. Effect of peritoneal fluid from patients with mild and severe endometriosis on endometrial stromal cell proliferation. Arch Gynecol Obstet. 1997;259(3):109–115.
  • Ricci AG, Olivares CN, Bilotas MA, et al. Natural therapies assessment for the treatment of endometriosis. Hum Reprod. 2013;28(1):178–188.
  • Revised American Fertility Society classification of endometriosis: 1985. Fertil Steril. 1985;43:351–352.
  • Aliani F, Ashrafi M, Arabipoor A, et al. Comparison of the symptoms and localisation of endometriosis involvement according to fertility status of endometriosis patients. J Obstet Gynaecol. 2018;38(4):536–542.
  • Shi X, Wang J, Lei Y, et al. Research progress on the PI3K/AKT signaling pathway in gynecological cancer. Mol Med Rep. 2019;19(6):4529–4535.
  • Lee TY, Martinez-Outschoorn UE, Schilder RJ, et al. Metformin as a therapeutic target in endometrial cancers. Front Oncol. 2018;8:341.
  • Liu H, Zhang L, Zhang X, et al. PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy. Onco Targets Ther. 2017;10:2865–2871.
  • Matsuzaki S, Pouly JL, Canis M. In vitro and in vivo effects of MK2206 and chloroquine combination therapy on endometriosis: autophagy may be required for regrowth of endometriosis. Br J Pharmacol. 2018;175(10):1637–1653.
  • Kacan T, Yildiz C, Baloglu KS, et al. Everolimus as an mTOR inhibitor suppresses endometriotic implants: an experimental rat study. Geburtshilfe Frauenheilkd. 2017;77:66–72.
  • Guo SW, Groothuis PG. Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? Hum Reprod Update. 2018;24(5):577–598.
  • Barra F, Ferro DL, Ferrero S. Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis. Br J Pharmacol. 2018;175(17):3626–3627.
  • Gonzalez-Ramos R, Donnez J, Defrere S, et al. Nuclear factor-kappa B is constitutively activated in peritoneal endometriosis. Mol Hum Reprod. 2007;13:503–509.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.